N-{1-cyano-2-[(phenylmethyl)oxy]ethyl}butanamide | 1093261-82-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-{1-cyano-2-[(phenylmethyl)oxy]ethyl}butanamide
• 英文别名: 3-Benzyloxy-a-(N-butyryl)-aminopropionitrile；N-(1-cyano-2-phenylmethoxyethyl)butanamide
• CAS: 1093261-82-5
• 化学式: C₁₄H₁₈N₂O₂
• 分子量: 246.309
• InChiKey: NFFBIFBOPUOFDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  62.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-{1-cyano-2-[(phenylmethyl)oxy]ethyl}butanamide 在 四氯化碳 、 manganese(IV) oxide 、 甲烷磺酸 、 三苯基膦 作用下， 以 1,4-二氧六环 、 氯仿 、 乙腈 为溶剂， 反应 19.0h， 生成 4-chloro-2-propyl-1H-imidazole-5-carboxaldehyde
  参考文献：
  名称：

  Rational Design of Potent Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase

  摘要：

  A new series of non-nucleoside reverse transcriptase inhibitors based on an imidazole-amide biarylether scaffold has been identified and shown to possess potent antiviral activity against HIV-1, including the NNRTI-resistant Y188L mutated virus. X-ray crystallography of inhibitors bound to reverse transcriptase, including a structure of the Y188L RT protein, was used extensively to help identify and optimize the key hydrogen-bonding motif. This led directly to the design of compound 43 that exhibits remarkable antiviral activity (EC50 < 1 nM) against a wide range of NNRTI-resistant viruses and a favorable pharmacokinetic profile across multiple species.

  DOI：

  10.1021/jm301294g
• 作为产物：
  描述：

  苄氧基乙醛 在 吡啶 、 ammonium hydroxide 、 氯化铵 作用下， 反应 50.0h， 生成 N-{1-cyano-2-[(phenylmethyl)oxy]ethyl}butanamide
  参考文献：
  名称：

  Rational Design of Potent Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase

  摘要：

  A new series of non-nucleoside reverse transcriptase inhibitors based on an imidazole-amide biarylether scaffold has been identified and shown to possess potent antiviral activity against HIV-1, including the NNRTI-resistant Y188L mutated virus. X-ray crystallography of inhibitors bound to reverse transcriptase, including a structure of the Y188L RT protein, was used extensively to help identify and optimize the key hydrogen-bonding motif. This led directly to the design of compound 43 that exhibits remarkable antiviral activity (EC50 < 1 nM) against a wide range of NNRTI-resistant viruses and a favorable pharmacokinetic profile across multiple species.

  DOI：

  10.1021/jm301294g

文献信息

• Process for preparing 2,4,5-trisubstituted imidazoles from N-acylated alpha-amino nitriles
  申请人：——

  公开号：US20040267026A1

  公开（公告）日：2004-12-30

  The invention is a process for preparing an imidazole of formula I 1 which comprises treating an N-acylated &agr;-amino nitrile with a phosphine and a carbon tetrahalide of the formula CX 4 , wherein X is Cl or Br, to form a haloimidazole of the formula 2 wherein R 1 is selected from the group consisting of hydrogen, C 1-6 alkyl, —CH 2 -aryl, and aryl; and R 2 is selected from the group consisting of hydrogen, C 1-6 alkyl, —CH 2 —O-aryl and aryl; and X is selected from the group consisting of Cl and Br.

  这项发明是一种制备式I1咪唑的过程，包括将N-酰化的α-氨基腈与膦和化学式CX4的碳四卤化物（其中X为Cl或Br）反应，形成式2的卤代咪唑，其中R1选自氢、C1-6烷基、—CH2-芳基和芳基组成的群；R2选自氢、C1-6烷基、—CH2—O-芳基和芳基组成的群；X选自Cl和Br组成的群。
• CHEMICAL COMPOUNDS
  申请人：Chong PEK Yoke

  公开号：US20100216746A1

  公开（公告）日：2010-08-26

  The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.

  本发明涉及一种非核苷类逆转录酶抑制剂，以及制备和使用该类化合物的方法。具体而言，本发明包括使用这些化合物治疗人类免疫缺陷病毒感染的方法。
• Chemical compounds
  申请人：GlaxoSmithKline LLC

  公开号：US08304419B2

  公开（公告）日：2012-11-06

  The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.

  本发明涉及一种非核苷类逆转录酶抑制剂化合物，以及制备和使用该化合物的方法。具体而言，本发明涉及使用这些化合物治疗人类免疫缺陷病毒感染的方法。
• WO2008/154271
  申请人：——

  公开号：——

  公开（公告）日：——
• US8304419B2
  申请人：——

  公开号：US8304419B2

  公开（公告）日：2012-11-06